Sentinel lymph node (SLN) status alone is not sufficient as node negative patients still experience relapse and melanoma-related death. Validates Merlin CP-GEP’s prognostic power: Identifying tumors at high-risk for relapse that would otherwise be missed by traditional clinical and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.